ReGen Declines "Futile" 510(k) Rescission Hearing But Plans Legal Challenge
This article was originally published in The Gray Sheet
Executive SummaryReGen Biologics says it is considering several last-ditch options to keep its collagen meniscus scaffold device on the U.S. market, but they do not include another hearing with FDA.
You may also be interested in...
U.S. District Court rules in FDA’s favor on 510(k) clearance rescission. Gastroenterology & Urology Devices panel to meet in June. More regulatory news.